CD52 and mature T-cell and NK-cell non-Hodgkin lymphoma: Alemtuzumab, a humanized anti-CD52 monoclonal antibody, was studied in a phase II study of 14 patients with heavily-pretreated PTCL, resulting in an ORR of 36%.